Cedar Mountain Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
Other funds holding SUPN
HWAM
WCM
YIH
FSA
EA
YCM
CWP
QCM
Cedar Mountain Advisors's SUPN Position: Q2 2026 in Review
Cedar Mountain Advisors held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 183 shares worth $8.51K. The position accounts for ﹤0.01% of the portfolio, ranked #537.
Cedar Mountain Advisors first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.46K in Q1 2026. 27 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Cedar Mountain Advisors held 183 shares of Supernus Pharmaceuticals worth $8.51K as of Q2 2026.
- Cedar Mountain Advisors left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
- Supernus Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #537 holding.
- Cedar Mountain Advisors first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
- Cedar Mountain Advisors's Supernus Pharmaceuticals position peaked at $9.46K in Q1 2026.
- 27 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.